Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Overall survival of gastric cancer remains low, as patients are often diagnosed with advanced stage disease. In this review, we give an overview of current research on biomarkers in gastric cancer and their implementation in treatment strategies. The HER2-targeting trastuzumab is the first molecular...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nadja Niclauss, Ines Gütgemann, Jonas Dohmen, Jörg C. Kalff, Philipp Lingohr
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	gastric cancer advanced gastric cancer biomarker targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d9b7fe0ecc1249cd8def507e944b250c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d9b7fe0ecc1249cd8def507e944b250c
record_format	dspace
spelling	oai:doaj.org-article:d9b7fe0ecc1249cd8def507e944b250c2021-11-25T17:02:20ZNovel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives10.3390/cancers132256602072-6694https://doaj.org/article/d9b7fe0ecc1249cd8def507e944b250c2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5660https://doaj.org/toc/2072-6694Overall survival of gastric cancer remains low, as patients are often diagnosed with advanced stage disease. In this review, we give an overview of current research on biomarkers in gastric cancer and their implementation in treatment strategies. The HER2-targeting trastuzumab is the first molecular targeted agent approved for gastric cancer treatment. Other promising biomarkers for targeted therapies that have shown relevance in clinical trials are VEGF and Claudin 18.2. Expression of MET has been shown to be a negative prognostic factor in gastric cancer. Targeting the PD-1/PD-L1 pathway with immune checkpoint inhibitors has proven efficacy in advanced gastric cancer. Recent technology advances allow the detection of circulating tumor cells that may be used as diagnostic and prognostic indicators and for therapy monitoring in gastric cancer patients. Prognostic molecular subtypes of gastric cancer have been identified using genomic data. In addition, transcriptome profiling has allowed a comprehensive characterization of the immune and stromal microenvironment in gastric cancer and development of novel risk scores. These prognostic and predictive markers highlight the rapidly evolving field of research in gastric cancer, promising improved treatment stratification and identification of molecular targets for individualized treatment in gastric cancer.Nadja NiclaussInes GütgemannJonas DohmenJörg C. KalffPhilipp LingohrMDPI AGarticlegastric canceradvanced gastric cancerbiomarkertargeted therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5660, p 5660 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gastric cancer advanced gastric cancer biomarker targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	gastric cancer advanced gastric cancer biomarker targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nadja Niclauss Ines Gütgemann Jonas Dohmen Jörg C. Kalff Philipp Lingohr Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
description	Overall survival of gastric cancer remains low, as patients are often diagnosed with advanced stage disease. In this review, we give an overview of current research on biomarkers in gastric cancer and their implementation in treatment strategies. The HER2-targeting trastuzumab is the first molecular targeted agent approved for gastric cancer treatment. Other promising biomarkers for targeted therapies that have shown relevance in clinical trials are VEGF and Claudin 18.2. Expression of MET has been shown to be a negative prognostic factor in gastric cancer. Targeting the PD-1/PD-L1 pathway with immune checkpoint inhibitors has proven efficacy in advanced gastric cancer. Recent technology advances allow the detection of circulating tumor cells that may be used as diagnostic and prognostic indicators and for therapy monitoring in gastric cancer patients. Prognostic molecular subtypes of gastric cancer have been identified using genomic data. In addition, transcriptome profiling has allowed a comprehensive characterization of the immune and stromal microenvironment in gastric cancer and development of novel risk scores. These prognostic and predictive markers highlight the rapidly evolving field of research in gastric cancer, promising improved treatment stratification and identification of molecular targets for individualized treatment in gastric cancer.
format	article
author	Nadja Niclauss Ines Gütgemann Jonas Dohmen Jörg C. Kalff Philipp Lingohr
author_facet	Nadja Niclauss Ines Gütgemann Jonas Dohmen Jörg C. Kalff Philipp Lingohr
author_sort	Nadja Niclauss
title	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
title_short	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
title_full	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
title_fullStr	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
title_full_unstemmed	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
title_sort	novel biomarkers of gastric adenocarcinoma: current research and future perspectives
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d9b7fe0ecc1249cd8def507e944b250c
work_keys_str_mv	AT nadjaniclauss novelbiomarkersofgastricadenocarcinomacurrentresearchandfutureperspectives AT inesgutgemann novelbiomarkersofgastricadenocarcinomacurrentresearchandfutureperspectives AT jonasdohmen novelbiomarkersofgastricadenocarcinomacurrentresearchandfutureperspectives AT jorgckalff novelbiomarkersofgastricadenocarcinomacurrentresearchandfutureperspectives AT philipplingohr novelbiomarkersofgastricadenocarcinomacurrentresearchandfutureperspectives
_version_	1718412807586709504

Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives

Ejemplares similares